Taft Pharmaceutical Litigation attorney Andrew M. Alul is quoted in the Oct. 3 article “Supreme Court Denies Review in Hatch-Waxman Case,” published in BNA’s Life Sciences Law Report. Alul commented on safe harbor protection and post-marketing activity. Read the article here.
Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.